Health Condition 1: null- Psoriasis with metabolic syndrome
Conditions
Interventions
Intervention1: METFORMIN: Insulin sensitizer
Intervention2: METFORMIN, PSORIASIS TREATMENT, LIFESTYLE INTERVENTION: Metformin 500 mg OD orally for 12 weeks
Prescribed psoriasis treatment
Lifestyle int
Sponsors
Post graduate Institute of Medical Education and Research PGIMER Chandigarh
Eligibility
Inclusion criteria
Inclusion criteria: 1. Patients with stable plaque psoriasis having mild to moderate disease severity not requiring systemic therapy i.e., PASI 1-10 and involvement of 2. Metabolic syndrome i.e., the presence of three or more criteria of the Consensus definition for Asian Indians: (i) Waist circumference > 90 cm in men and > 80 cm in women (ii) Hypertriglyceridemia > 150 mg/dl (iii) High density lipoprotein (HDL) cholesterol Men (iv) Blood pressure > 130/85 mm Hg (v) Fasting Blood glucose > 100 mg/dl 3. Patients willing to provide written informed consent
Exclusion criteria
Exclusion criteria: 1. Psoriasis patients with severe disease (Involvement of >10% body surface area and PASI > 10) 2. Patients with guttate, erythrodermic, or pustular psoriasis and psoriatic arthritis. 3. Patients receiving systemic treatment. 4. History, clinical findings on current examination indicative of cardiovascular disease. 5. Renal insufficiency - serum creatinine >=1.5 mg/dL (men) or >=1.4mg/dL (women). 6. Patients with significant hepatic impairment (serum bilirubin, AST, ALT and alkaline phosphatase >1.5 times the upper limit of normal). 7. Pregnant or nursing women. Women of childbearing potential will be considered potentially eligible provided they are following barrier method of contraception. 8. Any other chronic medical illness that may jeopardise interpretation of study results
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| To evaluate the effect of metformin on serum YKL-40, Asymmetrical dimethyl arginine (ADMA) and peak Flow Mediated Dilation (FMD).Timepoint: After 12 weeks | — |
Secondary
| Measure | Time frame |
|---|---|
| To compare the levels of Serum YKL-40, Serum Asymmetrical Dimethyl Arginine and peak Flow Mediated Dilation in psoriasis patients with and without metabolic syndrome and in patients with various dermatosis without metabolic syndrome.Timepoint: After 12 weeks;To evaluate the correlation of markers of endothelial dysfunction with change in Psoriasis Area Severity Index (PASI).Timepoint: After 12 weeks | — |
Countries
India
Contacts
Public ContactDr Krishna Prashanti
PGIMER
Outcome results
None listed